Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation - Full Text View

Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation (RESTORATION)

This study is currently recruiting participants.
Verified by Sequel Pharmaceuticals, Inc, August 2008

Sponsored by:	Sequel Pharmaceuticals, Inc
Information provided by:	Sequel Pharmaceuticals, Inc
ClinicalTrials.gov Identifier:	NCT00626652

Purpose

To evaluate the effects of K201 on sinus rhythm restoration, symptom score, various cardiovascular parameters, and safety.

Condition	Intervention	Phase
Atrial Fibrillation	Drug: K201 Injection	Phase II

Genetics Home Reference related topics:

Brugada syndrome familial atrial fibrillation short QT syndrome

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment

Official Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Effects of K201 Injection, 2 mg/mL on the Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation

Further study details as provided by Sequel Pharmaceuticals, Inc:

Primary Outcome Measures:

Restoration of sinus rhythm [ Time Frame: 24hrs ] [ Designated as safety issue: No ]

Estimated Enrollment:	60
Study Start Date:	March 2008
Estimated Study Completion Date:	November 2008
Estimated Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: K201 Injection single intravenous infusion, Dose 1, 2, 3, 4 or placebo

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Symptomatic atrial fibrillation
Atrial fibrillation documented by ECG
Adherence to local clinical standards or the ACC/AHA/ESC practice guidelines for atrial fibrillation regarding thrombo-embolic event prevention and treatment.

Exclusion Criteria:

Systolic blood pressure <100 mmHg
Heart rate <50 bpm
Temperature >38°C
QT or QTcB >440 ms
QRS >140 ms
Paced atrial or ventricular rhythm on ECG
Serum potassium <3.5 meq/L
History of receiving another intravenous Class I or Class III antiarrhythmic drug within 3 days of randomization
History of amiodarone in last 6 months.
Clinical evidence of acute coronary syndrome
Acute pulmonary edema or embolism
Hyperthyroidism
Acute pericarditis
History of failed electrical cardioversion at any time
History of torsades des pointes
History of familial long QT interval syndrome
History of ventricular tachycardia requiring drug or device therapy
History of NYHA Heart Failure Class 3 or 4.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00626652

Contacts


Contact: Howard C Dittrich, MD	858.405.1429	HDittrich@SequelPharma.com

Contact: Paul Chamberlin, MD	858.523.4515	PChamberlin@SequelPharma.com

Locations


Israel
		Recruiting
	Ashkelon, Israel
		Not yet recruiting
	Hadera, Israel
		Not yet recruiting
	Holon, Israel
		Not yet recruiting
	Jerusalem, Israel
		Recruiting
	Nazareth, Israel
		Recruiting
	Safed, Israel
		Recruiting
	Zeriffin, Israel

Russian Federation
		Recruiting
	Moscow, Russian Federation
		Recruiting
	St Petersburg, Russian Federation

Sponsors and Collaborators

Sequel Pharmaceuticals, Inc

Investigators


Principal Investigator:	Sergey Pavlovich Golitsyn, Prof.	Russian Cardiologic Scientific and Manufacturing Complex of Roszdrav, Institute of Cardiology n.a. A.L.Myasnikov, Department of clinical electrophysiology

Principal Investigator:	Amos Katz, Prof.	Barzilai Medical Center

More Information

Responsible Party:	Sequel Pharmaceuticals ( Howard C. Dittrich, MD; Chief Medical Officer )
Study ID Numbers:	CJI-201
First Received:	February 18, 2008
Last Updated:	August 13, 2008
ClinicalTrials.gov Identifier:	NCT00626652
Health Authority:	Israel: Ministry of Health; Russia: Ministry of Health and Social Development of the Russian Federation

Study placed in the following topic categories:

Heart Diseases

Atrial Fibrillation

Arrhythmias, Cardiac

Additional relevant MeSH terms:

Pathologic Processes

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 15, 2008